| Document |
Document Title |
|
WO/2023/037218A1 |
Described herein are methods of treating early or intermediate age-related macular degeneration with the Factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof, e.g. iptacopan hydrochloride.
|
|
WO/2023/036227A1 |
The present invention belongs to the field of medicine, and specifically relates to atropine eye drops and a preparation method therefor. The atropine eye drops provided in the present invention comprise: by mass concentration, 0.10-0.20...
|
|
WO/2023/035950A1 |
A method for treating retinal degeneration, the method comprising administering a microbial inhibitor or biocide to the eye or gastrointestinal tract of a patient; specifically, by means of establishing an eye disease model or an eye dis...
|
|
WO/2023/039458A1 |
A method of treating an eye disorder in a patient that may include administering a medicament to the patient with a prefilled syringe, wherein the administration of the medicament with the prefilled syringe is configured to treat the eye...
|
|
WO/2023/039089A1 |
The invention relates to a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, compositions comprising the same and methods of preparing and using the same.
|
|
WO/2023/038974A1 |
Disclosed herein are methods of treating a condition affecting nerve tissue, skin tissue, organ tissue, or vascular tissue using a placenta-derived composition comprising placental tissue and one or more protease inhibitors. Also disclos...
|
|
WO/2023/038924A1 |
Disclosed herein are methods of treating a condition affecting bone tissue, muscle tissue, or connective tissue using a placenta-derived composition comprising placental tissue and one or more protease inhibitors. Also disclosed herein a...
|
|
WO/2023/039168A1 |
Methods for reducing the risk of fibrosis or scarring after an ocular surgical procedure or ocular injury are disclosed. In particular, one or more therapeutically effective doses of verteporfin are administered to a subject before, duri...
|
|
WO/2023/039599A1 |
Methods and compositions are provided for enhancing endoplasmic reticulum-associated degradation (ERAD) and suppressing pathological accumulation of misfolded proteins in cells by increasing expression or activity of zinc transporter pro...
|
|
WO/2023/036966A1 |
The present invention is based on the observation that a dual AAV vector strategy encoding isoform 5 of otoferlin cDNA that has been split into two expression cassettes both packaged in - and delivered by - an AAV8 capsid can efficiently...
|
|
WO/2023/030430A1 |
An ophthalmic formulation for preventing and treating cataracts by eye drop administration, composed of an active substance for treating eye diseases and a pharmaceutically acceptable carrier or excipient. The active substance for treati...
|
|
WO/2023/034898A1 |
This invention relates to methods and compositions for inhibiting fibrosis and the formation of scars, e.g., as a result of corneal wounds, by administering NBL1 to a subject. The invention further relates to methods and compositions for...
|
|
WO/2023/033500A1 |
The present invention relates to a composition containing extracellular vesicles derived from mesenchymal stem cells, wherein the extracellular vesicles are exosomes isolated from bone marrow-derived mesenchymal stem cells using an aqueo...
|
|
WO/2023/034899A1 |
Methods for assessing efficacy of a treatment for a bestrophinopathy in a subject are provided. In certain embodiments, the subject has two mutant BEST1 alleles. In certain embodiments, the subject has at least one mutant BEST1 allele. I...
|
|
WO/2023/032940A1 |
The present invention provides a compound which has PDHK inhibitory activity and which is useful for treating or preventing diabetes (type 1 diabetes, type 2 diabetes, etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia...
|
|
WO/2023/029281A1 |
Provided in the present invention are an anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and the use thereof. The monoclonal antibody has high affinity for human TSLP, has a neutralizing activity, and can be used for p...
|
|
WO/2023/033483A1 |
The present invention relates to a pharmaceutical composition for preventing or treating diabetic eye disease, comprising sodium-glucose cotransporter-2 (SGLT-2) inhibitor, and a method for preventing or treating diabetic eye disease by ...
|
|
WO/2023/031319A1 |
The present invention relates to novel 2,4-dihydro-3H-1,2,4-triazol-3-one compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for prepar...
|
|
WO/2023/029661A1 |
Provided in the present invention is the use of a reagent for promoting miR-21 expression in the preparation of a drug for preventing and/or treating diabetic keratopathy, which belongs to the technical field of biological medicines. Acc...
|
|
WO/2023/032987A1 |
Provided are: a 6-aminopyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; and a pharmaceutical use thereof. A ...
|
|
WO/2023/029280A1 |
Provided in the present application are an anti-human interleukin-33 monoclonal antibody and the use thereof. The monoclonal antibody has a high affinity for human interleukin-33, has neutralizing activity, and can be used for preventing...
|
|
WO/2023/031277A1 |
Ocular Rosacea (OR) is a chronic inflammatory and neurovascular diseases of the ocular surface and eyelids, associated with abnormal tear film lipids that can lead to corneal neovascularization, loss of transparency and ulceration. Here,...
|
|
WO/2023/028490A1 |
This invention is directed to a method of preventing and/or treating ocular pain in a subject in need thereof.
|
|
WO/2023/028004A1 |
Described herein are compositions for modulating transgene expression. Also described herein are methods for using the compositions described herein for modulating transgene expression.
|
|
WO/2023/024134A1 |
A use of a fibrillin-2 (FBN2) recombinant protein in the preparation of products for preventing or treating FBN2 deficiency eye diseases. By constructing an FBN2 gene deficiency eye disease mouse model by means of intravitreal injection ...
|
|
WO/2023/025861A1 |
The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein X, R1, R2, R3 are defined, a conjugate thereof and their uses as drug or research tools.
|
|
WO/2023/027430A1 |
The present invention provides an aqueous eye drop solution composition comprising: lifitegrast or a pharmaceutically acceptable salt thereof; a citric acid, a citric acid salt, or a combination of a citric acid and a citric acid salt as...
|
|
WO/2023/025273A1 |
Provided is a VEGF binding molecule, comprising an immunoglobulin single variable domain. Also provided are a nucleic acid molecule encoding the VEGF binding molecule, an expression vector for expressing the VEGF binding molecule, and a ...
|
|
WO/2023/020535A1 |
An application of a steroid compound in the preparation of a drug for preventing and/or treating eye floaters. The steroid compound can have good therapeutic, alleviative, and preventive effects on eye floaters, can alleviate and/or cure...
|
|
WO/2023/023305A1 |
Degenerative macular diseases are a major cause of incurable blindness. The present disclosure relates to cell-based therapeutics for retinal and macular repair comprising defined retinal cell subtypes, including short (S)-, medium (M)- ...
|
|
WO/2023/020488A1 |
A use of and method for telaprevir in the preparation of a drug and a cytoprotective drug for treating ischemia/reperfusion injury. Telaprevir is used for the preparation of a drug for treating ischemia/reperfusion injury, in particular ...
|
|
WO/2023/020536A1 |
A pharmaceutical composition, a preparation method therefor and an application thereof. The pharmaceutical composition comprises the following components: a compound represented by formula I, hydroxypropyl methyl cellulose, benzalkonium ...
|
|
WO/2023/021492A1 |
A stable nanomicellar ophthalmic solution comprising cyclosporine and a method of preparing the nanomicellar solution. The present invention further relates to a stable nanomicellar solution comprising a cyclosporine form with characteri...
|
|
WO/2023/019687A1 |
An ion-sensitive ophthalmic in-situ gel, comprising combretastatin n-butylammonium salt, a solubilizer, an ion-sensitive gel, water for injection, and pharmaceutically acceptable auxiliary ingredients. In every 100 mL ion-sensitive ophth...
|
|
WO/2023/023256A1 |
The present invention relates generally to gene therapy for treating ailments that can affect vision such as retinal degeneration, retinal dystrophy, macular degeneration, macular dystrophy, ischemic retinopathies, and glaucoma. Embodime...
|
|
WO/2023/022390A1 |
A composition containing a Dendropanax morbifera LEV. extract, of the present invention, has excellent activities of inhibiting the oxidation of A2E, inhibiting oxidized A2E-induced death of retinal pigmented epithelial cells, and inhibi...
|
|
WO/2023/019688A1 |
An intravitreal injection agent. The intravitreal injection agent is prepared from raw materials: a combretastatin n-butyl ammonium salt, an osmotic pressure adjusting agent, a pH adjusting agent and water. The massic volume concentratio...
|
|
WO/2023/019949A1 |
Disclosed is the use of a nitrate and vitamin C microcapsule in the preparation of a drug for treating sicca syndrome. The microcapsule comprises a wall material and a core material encapsulated in the wall material, wherein the core mat...
|
|
WO/2023/019218A1 |
Described herein are methods of preventing, treating or ameliorating a disease, disorder or a condition associated with fibrotic diseases, comprising administering to a subject having a fibrotic disease a pharmaceutically effective amoun...
|
|
WO/2023/019171A1 |
Antibodies and compositions against IGF-1R and uses thereof are provided herein.
|
|
WO/2023/014117A1 |
The present invention relates to an eye drop composition for treating dry eye syndrome, containing recoflavone. Particularly, the present invention relates to an eye drop composition which, by containing a certain concentration or higher...
|
|
WO/2023/011251A1 |
A rapid and efficient clinical grade pigment epithelium induction method, a kit, and an application. Provided is a method for rapidly and efficiently inducing retinal pigment epithelium (RPE). IPSCs are directionally induced in three sta...
|
|
WO/2023/013628A1 |
[Problem] To provide an eyewash composition that contains propylene glycol but yet has excellent antiseptic properties. [Solution] An eyewash composition that contains 0.01 w/v% or more of at least one selected from the group consisting ...
|
|
WO/2023/010897A1 |
Provided are a method for differentiating human induced pluripotent stem cells into oligodendrocytes, and a kit and the use. The method comprises culturing stem cells by means of using at least one of the following culture media: a neura...
|
|
WO/2023/013993A1 |
Disclosed is a pharmaceutical composition containing EW-7197 (2-fluoro-N-((5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,
5-a]pyridin-6-yl)-1H-imidazol-2-yl)methyl)aniline), a pharmaceutically acceptable salt thereof, or a solvate thereo...
|
|
WO/2023/012754A1 |
The present invention provides an ophthalmic composition for the treatment and/or prevention of visual disorders caused by changes in the structure of the eye lens, in particular changes related to an alteration in the proteins forming t...
|
|
WO/2023/014113A1 |
The present invention relates to an eye drop comprising recoflavone for treatment of xerophthalmia. Specifically, the present invention relates to an eye drop composition wherein a main ingredient is contained at a certain concentration ...
|
|
WO/2023/014892A1 |
Disclosed herein are novel compositions, engineered cells and cell lines, as well as related method of treating ocular diseases or conditions, such as neovascular age-related macular degeneration, diabetic retinopathy, glaucoma, corneal ...
|
|
WO/2023/013409A1 |
The present disclosure relates to providing a cytoprotectant and a thermal oxidation inhibitor that protect the skin from infrared damage and heat damage. More particularly, there are provided a cytoprotectant and a thermal oxidation inh...
|
|
WO/2023/011632A1 |
Provided is a recombinant nucleic acid, comprising: a mitochondrial targeting sequence, a mitochondrial protein coding sequence, a 3'UTR nucleic acid sequence, and a polyadenylate tail sequence, wherein the mitochondrial protein coding s...
|
